

# **Vascular-water-exchange MRI (VEXI) enables the detection of subtle BBB breakdown in Alzheimer's disease without MRI contrast agent**

Yifan Zhang<sup>1,2#</sup>, Yue Wang<sup>3,4#</sup>, Zhaoqing Li<sup>1,2</sup>, Zejun Wang<sup>1,2</sup>, Juange Cheng<sup>1</sup>, Xiaoyan Bai<sup>5,6</sup>, Yi-Cheng Hsu<sup>7</sup>, Yi Sun<sup>7</sup>, Shiping Li<sup>3,4,8</sup>, Jiong Shi<sup>3,4,8\*</sup>, Binbin Sui<sup>3\*</sup>, Ruiliang Bai<sup>1,2,9\*</sup>

<sup>1</sup>Department of Physical Medicine and Rehabilitation of the Affiliated Sir Run Shaw Hospital AND Interdisciplinary Institute of Neuroscience and Technology, School of Medicine, Zhejiang University, Hangzhou, China

<sup>2</sup>Key Laboratory of Biomedical Engineering of Education Ministry, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, China

<sup>3</sup>National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

<sup>4</sup>Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

<sup>5</sup>Tiantan Neuroimaging Center of Excellence, China National Clinical Research Center for Neurological Diseases, Beijing, China

<sup>6</sup>Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing Neurosurgical Institute, Beijing, China

<sup>7</sup>MR Collaboration, Siemens Healthcare, Shanghai, China

<sup>8</sup>Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China

<sup>9</sup>MOE Frontier Science Center for Brain Science and Brain-machine Integration, School of Brain Science and Brain Medicine, Zhejiang University

# These authors make equally contribution to this manuscript.

**\*Corresponding author:** Dr. Ruiliang Bai;

Address: 268 Kaixuan Road, South Central Building, Room 708, Hangzhou, Zhejiang, China, 310027; Phone: 0571-8697112; E-Mail: [ruiliangbai@zju.edu.cn](mailto:ruiliangbai@zju.edu.cn)

Dr. Binbin Sui: Address: No.119, West Road of South 4th Ring Road, Fengtai District, Beijing 100070 China; TEL: 86-10-59975392; Email: [reneesui@163.com](mailto:reneesui@163.com)

1 Dr. Jiong Shi: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No.  
2 119, South Fourth Ring West Road, Fengtai District, Beijing, China, 100070, Tel +86-10-59978350,  
3 Fax +86-10-59973383; Email: [jjiongshi@nrcnd.org.cn](mailto:jjiongshi@nrcnd.org.cn)

4

5

## 6 **Abstracts**

7 Blood-brain barrier (BBB) impairment is an important pathophysiological process in Alzheimer's  
8 disease (AD) and a potential biomarker for early diagnosis of AD. However, most current  
9 neuroimaging methods assessing BBB function need the injection of exogenous contrast agents (or  
10 tracers), which limits the application of these methods in a large population. In this study, we aim  
11 to explore the feasibility of vascular water exchange MRI (VEXI), a diffusion-MRI-based method  
12 to assess the BBB permeability to water molecules without using a contrast agent, in the detection  
13 of the BBB breakdown in AD. We tested VEXI on a 3T MRI scanner on three groups: AD patients  
14 (AD group), mild cognitive impairment (MCI) patients due to AD (MCI group), and the age-  
15 matched normal cognition subjects (NC group). Interestingly, we find that VEXI can detect the BBB  
16 permeability to water molecules increase in MCI and this BBB breakdown happens specifically in  
17 the hippocampus. This BBB breakdown gets worse and extends to more brain regions (orbital  
18 frontal cortex and thalamus) from MCI group to the AD group. Furthermore, we find that the BBB  
19 breakdown of these three regions detected by VEXI is correlated significantly with impairment of  
20 respective cognitive domains independent of age, sex and education. These results suggest VEXI is  
21 a promising method to assess the BBB breakdown in AD.

22

23

# 1     **Highlights**

- 2     •    The vascular water exchange MRI (VEXI) is a contrast-agent-free method to assess BBB
- 3       permeability
- 4     •    BBB breakdown happens specifically in the hippocampus, orbital frontal cortex, and thalamus
- 5       in AD
- 6     •    BBB breakdown detected by VEXI is significantly correlated with cognitive dysfunction

# 8     **Keywords**

9     Blood-brain barrier, contrast-agent-free, water exchange, Alzheimer's disease, permeability

# 1. Introduction

Increasing evidence has shown that blood-brain barrier (BBB) impairment is a contributing factor in the pathophysiology of Alzheimer's disease (AD) (Iadecola, 2017; Sweeney et al., 2018). BBB is a continuous endothelial membrane within brain microvessels that seals cell-to-cell contacts, regulates the delivery of important nutrients to the brain, and prevents neuro-toxins from entering the brain (Zlokovic, 2008). It also has a clearance function to remove excess substances from the brain. BBB structure and function can be assessed with neuropathology in postmodern samples (Arvanitakis et al., 2016; Toledo et al., 2013), neuroimaging methods (Kisler et al., 2017; Montagne et al., 2015; Sweeney et al., 2018; van de Haar et al., 2017, 2016), and cerebrospinal fluid biomarkers (Iturria-Medina et al., 2016; Montagne et al., 2015; Sagare et al., 2015; Sweeney et al., 2018), among which only neuroimaging methods could provide the spatial distribution features of BBB impairment *in vivo*. Studies using these neuroimaging methods, including positron emission tomography (PET) and MRI, have produced fruitful results of increased BBB permeability in different brain regions in AD patients (Minoshima et al., 1997; van de Haar et al., 2017, 2016; Wang et al., 2006) and its relationship with brain structural changes (e.g. atrophy) (Nation et al., 2019; Zhang et al., 2019). However, most conventionally used neuroimaging methods assessing BBB permeability in AD utilize the intravenous administration of contrast agents (or radioactive tracer). A non-invasive and contrast-agent-free neuroimaging method to characterize BBB permeability is still highly desirable.

Recently, there are several newly developed MRI methods aiming to measure the water exchange across BBB, which provides a novel means to assess BBB permeability without the usage of contrast agent (Dickie et al., 2020). These contrast-agent-free MRI techniques mainly include two different types of approaches. One is based on arterial spin labeling (ASL) technique, which uses ASL to label intravascular water and then monitor the dynamic change of labeled water in intravascular and extravascular spaces by using diffusion (He et al., 2018, 2012; Wang et al., 2007), multiple echo (Ohene et al., 2019), or phase contrast (Lin et al., 2018) methods. The second approach utilizes the filter-exchange imaging (FEXI), a technique adapted from diffusion exchange spectroscopy (DEXSY) for clinical applications (Lasič et al., 2011; Nilsson et al., 2013). By

exploring the intravoxel incoherent motion (IVIM) of capillary water, designing a proper diffusion weighting to filter out intravascular water specifically and then quantitatively monitoring the water exchange between intra- and extravascular space via the second diffusion encoding, FEXI shows the capacity for measuring the water exchange across BBB in human (Bai et al., 2020). More encouragingly, a recent study shows that the water exchange across BBB is a more sensitive biomarker in the detection of subtle BBB breakdown than the conventional biomarker of contrast agent leakage from BBB in an AD rat model, as water molecule is much smaller than MRI contrast agents and could potentially be more sensitive to BBB leakage (Dickie et al., 2019). However, it is still unknown if it is feasible to use the water-exchange based MRI method to detect the BBB leakage in AD patients.

In this study, we aim to explore the feasibility of the contrast-agent-free MRI method in the detection of subtle BBB impairment in AD patients. For this purpose, the FEXI-based vascular-water-exchange MRI (VEXI) was implemented on a 3T clinical MRI scanner to assess the BBB permeability to water molecules. MRI and cognitive function assessments were performed on three groups: AD patients (AD group), mild cognitive impairment due to AD patients (MCI group), and the age-matched normal cognition subjects (NC group). Both MCI and AD groups were diagnosed based on clinical criteria and positive amyloid-beta (A $\beta$ ) deposition confirmed by PET.

## 2. Methods

### 2.1. Study Participants

This study was a sub-study of an ongoing prospective community-based cohort study of the China National Clinical Research Center Alzheimer's Disease and Neurodegenerative Disorder Research (CANDOR). CANDOR was started in July 2019 and planned to enroll one thousand and five hundred participants, including individuals with NC, MCI, and dementia (including AD).

This sub-study recruited participants from March 2021 to January 2022. All the AD and MCI participants were recruited from Beijing Tiantan Hospital and the NC participants were recruited

from the local communities. Demographic information, past medical history, social and family history were collected. All participants underwent detailed cognitive assessments, including the battery of neuropsychological tests such as Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating (CDR), Rey Auditory Verbal Learning Test (RAVLT) etc., and brain MRIs. All enrolled participants for this study were (1) subjectively normal in NC groups, or diagnosed as MCI due to AD or AD. The diagnosis of MCI due to AD and AD was based on the National Institute on Aging-Alzheimer's Association guidelines for AD (Albert et al., 2011; McKhann et al., 2011) and positive amyloid status confirmed by  $^{11}\text{C}$ -labeled Pittsburgh Compound-B (PIB) PET-CT; (2) aged 40-100 years-old, (3) had at least 3 years of elementary-school education and could complete the neuropsychological tests independently; (4) had no conditions known to affect cognitive function, such as alcoholism, uncontrolled depression or other psychiatric disorders, Parkinson's disease, epilepsy, stroke and etc.

13

## 14 **2.2. Standard Protocol Approvals, Registrations, and Patient Consents**

This protocol was approved by the Institutional Review Board of Beijing Tiantan Hospital (approval number: KY 2019-004-007) and was in accordance with relevant guidelines and regulations. Written informed consent was obtained from each participant.

18

## 19 **2.3. Principles of vascular-water-exchange MRI (VEXI)**

VEXI characterizes the BBB permeability to water molecules, which is illustrated in **Figure 1**. It is a specific type of diffusion-based FEXI adapted for measuring the water exchange across BBB (Bai et al., 2020). Briefly, it contains three blocks, including the filter block, mixing block, and detection block. The filter block is a pulsed gradient spin echo (PGSE) with diffusion weighting  $b_f$ , in which  $b_f$  ( $= 250 \text{ s/mm}^2$ ) is optimized to filter the intravascular water magnetization showing nearly one-fold larger apparent diffusivity than the extravascular water magnetization due to IVIM (Le Bihan, 2019). After the first filter block, the remaining magnetization in the transverse plane is stored back in the longitudinal direction and kept for a certain mixing time ( $t_m$ ), during which water molecules exchange across BBB (mixing block). Finally, the filtered and mixed magnetization is put back to the transverse plane with the third  $90^\circ$  pulse and the apparent diffusivity ( $ADC'$ ) of the mixed water

pools is measured in the second PGSE block (detection block). A pair of identical gradients is implemented before the second 90 pulse and after the third 90 pulse such that the stimulated echo is formed after the second gradient and the unwanted magnetization (e.g., the inflowing blood from neighboring slices) is eliminated.

In VEXI,  $ADC'$  were acquired at several  $t_m$  (more water molecule exchange across BBB in longer  $t_m$ ) and the apparent water exchange rate constant across BBB ( $AXR_{BBB}$ ) could then be extracted from  $ADC'(t_m)$  signal (**Figure 1B**). Here it is assumed that the water molecules in brain tissue can be separated into “slow” (s, extravascular water pool) and “fast” (f, intravascular water pool, IVIM) diffusion components with apparent diffusivities  $D_s$  and  $D_f$ , and equilibrium fractional populations  $f_s^{eq}$  and  $f_f^{eq}$  ( $f_s^{eq} + f_f^{eq} = 1$ ), respectively. Water molecules are in exchange between the two water pools across BBB with a water exchange rate constant  $k_{fs}$  from the intravascular to the extravascular pool, and  $k_{sf} = k_{fs} f_f^{eq} / f_s^{eq}$  from the extravascular to the intravascular water pool. At a fixed  $b_f$ , the acquired MRI signal  $S$  is a function of the diffusion weighting in the detection block ( $b_d$ ) and  $t_m$  (Lasič et al., 2011; Nilsson et al., 2013),

$$S(b, t_m) = S'(t_m) \exp(-b ADC'(t_m)) \quad [1]$$

where  $S'(t_m)$  takes into consideration the effects of longitudinal relaxation during  $t_m$  and the apparent diffusion coefficient  $ADC'(t_m)$  is determined by the two water components' apparent diffusivity and exchange rate, using an approximation that applies when  $b$  approaches zero,

$$ADC'(t_m) = ADC_0 (1 - \sigma \exp(-t_m AXR_{BBB})) \quad [2]$$

$$ADC_0 = f_s^{eq} D_s + f_f^{eq} D_f \quad [3]$$

Here it is assumed that exchange is slow on the time scale of the duration of the PGSE blocks and that longitudinal relaxation rates are the same for both components.  $\sigma$  is the filter efficiency that quantifies the  $ADC'$  reduction at  $t_m = 0$ .  $AXR_{BBB}$  is the apparent water exchange rate constant across BBB and its relation with the intravascular water efflux rate constant  $k_{fs}$  is,

$$AXR_{BBB} = k_{fs} + k_{sf} = \frac{k_{fs}}{1 - f_f^{eq}} \quad [4]$$

, and  $AXR_{BBB}$  approaches to  $k_{fs}$  in gray or white matter as the intravascular water fraction  $f_f^{eq}$  is generally small (e.g., < 5%) in healthy brain or the degenerated brain. In this study,  $AXR_{BBB}$  is taken

as the quantitative parameter characterizing BBB permeability to water molecules.




Figure 1. Overview of the principles of VEXI implemented in this study. (A) VEXI pulse sequence. (B) Illustration of the MRI signal evaluation of intravascular and extracellular water molecule during VEXI acquisition. The first pulsed gradient spin echo (PGSE) block with diffusion weighting  $b_f$  is served as the filter of intravascular water pools, which showing large apparent diffusivity due to IVIM. After the first filter block, the remaining magnetization in the transverse plane is stored back in the longitudinal direction (mixing block) and kept for a certain mixing time ( $t_m$ ), during which water molecules exchange across BBB. Finally, the filtered and mixed magnetization is put back to the transverse plane with the third 90° pulse and the apparent diffusivity ( $ADC'$ ) of the mixed water pools is measured in the second PGSE block. In VEXI,  $ADC'$  were acquired at several  $t_m$  (more water molecules exchange across BBB in longer  $t_m$ ) and the apparent water exchange rate across BBB ( $AXR_{BBB}$ ) could then be extracted from  $ADC'(t_m)$  signal.

## 2.4. MRI protocols

MRI scans were performed with a 3.0T MRI clinical scanner (MAGNETOM Prisma, Siemens Healthcare, Erlangen, Germany), using a Nova 64-channel head RF coil. MRI scans included 3D MPAGE  $T_1$ -weighted images, diffusion-weighted images and VEXI. The  $T_1$ -weighted images were acquired with  $1.0 \times 1.0 \times 1.0 \text{ mm}^3$  resolution, TE/TR = 2.01/2000 ms, flip angle 8°, inversion time 880 ms. To characterize diffusion anisotropy, a diffusion tensor imaging (DTI) protocol was performed with TE/TR = 70/2800 ms, 5 repetitions on  $b = 0 \text{ s/mm}^2$  and 50 directions with single



1 repetition for each direction at  $b = 1000 \text{ s/mm}^2$ . The voxel size for the DTI images was  $2.0 \times 2.0 \times$   
2  $2.0 \text{ mm}^3$ . VEXI was performed at XZ direction with  $b_f = 250 \text{ s/mm}^2$  and two  $b$  values in the detection  
3 block ( $b_d = 0 \text{ s/mm}^2$  with 6 repetitions and  $250 \text{ s/mm}^2$  with 10 repetitions). Imaging was repeated  
4 with three mixing time ( $t_m$ ): 25, 200, and 400 ms. VEXI was also acquired with  $b_f = 0 \text{ s/mm}^2$  and  
5 shortest  $t_m$  (25 ms), echo time in the filter block  $TE_f = 26 \text{ ms}$ , echo time in the detection block  $TE =$   
6  $37 \text{ ms}$ , timings of the gradients in the filter block  $\Delta t/\delta_f = 11.5 \text{ ms} / 6.3 \text{ ms}$ , and timings of the  
7 gradients in the detection block  $\Delta/\delta = 14.4 \text{ ms} / 8.6 \text{ ms}$ . For the VEXI protocol, the voxel size was  
8  $3.0 \times 3.0 \times 5.0 \text{ mm}^3$ , and the number of slices was 20.

9

## 10 **2.5. VEXI data processing**

11 All DTI and VEXI data underwent pre-processing including motion and eddy current distortion  
12 correction in TORTOISE (Pierpaoli et al., 2010). For the DTI data, pre-processed DWIs were fit to  
13 non-linear DTI model and DTI metrics including mean diffusivity (MD) were generated with  
14 TORTOISE. For the VEXI data, the model fitting was performed with in-house programs developed  
15 in MATLAB (2018B, The MathWorks Inc., Natick, Massachusetts). Here, the  $ADC'(t_m)$  values  
16 were computed from the measurements with two  $b$  values in the detection block ( $b_{d1}$  and  $b_{d2}$ ) at  
17 each  $t_m$ , according to

$$18 \quad ADC'(t_m) = -\frac{1}{b_{d2}-b_{d1}} \ln\left(\frac{S(t_m, b_{d2})}{S(t_m, b_{d1})}\right) \quad [5]$$

19 where  $S(t_m, b_{d1})$  and  $S(t_m, b_{d2})$  are the VEXI signals acquired at  $b_{d1}$  and  $b_{d2}$ , respectively.  
20 Then the  $ADC'(t_m)$  at three  $t_m$  and  $b_f = 0$  (taken as equilibrium state, *i.e.*,  $t_m = +\text{Inf}$ ) were fitted to  
21 Eq. [2] with the trust-region nonlinear least-squares algorithm in each voxel to calculate the VEXI  
22 derived parameters,  $AXR_{\text{BBB}}$ ,  $ADC$  and  $\sigma$ .

23


## 24 **2.6 Region-of-interest (ROI) analysis**

25 We then generated a study-specific template with the  $T_1$ -weighted images of all subjects in NC  
26 group, using the ANTs script (Avants et al., 2010). DTI data with  $b=0 \text{ s/mm}^2$  and VEXI data with  
27  $b_f=0 \text{ s/mm}^2$  and  $b_d=0 \text{ s/mm}^2$  were linear registered to  $T_1$ -weighted images using ANTs (Avants et  
28 al., 2011). Afterwards, the  $T_1$ -weighted images in the native space were registered to our study-  
29 specific template using ANTs SyN algorithm. Parameter maps ( $AXR_{\text{BBB}}$ ,  $ADC$  and  $\sigma$ ) were then

iteratively aligned to the template by applying the linear registration transformation matrix and the deformation field generated above. In addition, we nonlinearly registered the MNI152  $T_1$ -weighted template (Mazziotta et al., 2001, 1995) to our template to transform some atlas defined in MNI152 template into our study- specific template space.

Region-of-interest (ROI) masks were extracted from Brainnetome Atlas (Fan et al., 2016) and JHU white matter Atlas (Mori et al., 2005). As shown in **Figure 2**, a total of 5 grey matter ROIs including the hippocampus, caudate nucleus, thalamus, striatum, and orbital frontal cortex (OFC) and 3 white matter ROIs including subcortical watershed white matter fibers, corpus callosum and internal capsule were chosen according to other studies in AD or MCI (Montagne et al., 2015). All the ROIs were bilateral. Several steps were implemented to reduce the potential confound induced by brain atrophy, which includes (1) one experienced neurologist was invited to readjust and double-check the hippocampus and other brain ROIs based on neuroanatomy, (2) the 3D structural images ( $T_1$  weighted) were segmented into CSF, gray matter, and white matter, and these selected brain ROIs (like hippocampus) were readjusted to remove the CSF voxels based on the segmented results; (3) voxels with MD larger than  $2.0 \text{ um}^2/\text{ms}$  were also considered as CSF voxels and further removed from these brain ROIs. The parametric metrics in each ROI were calculated as the median of all voxels in this ROI.

To double check the results obtained in the template space, the same ROI-level analysis was also performed in the subjects' native space. The 8 selected brain regions were manually drawn by one experienced neurologist on each subject's native space. CSF voxels were removed using the same methods in the template space. The parametric metrics in each ROI were also calculated as the median of all voxels in this ROI.



**Figure 2.** Eight regions of interest based on Brainnetome atlas and JHU white matter atlas in the customized-template space. Here different ROIs were represented with different numbers.

1

## 2 **2.7 Volumetric analysis**

3 For the regional level volumetric analysis, all the  $T_1$ -weighted images were processed through the  
 4 voxel-based-morphometry (VBM) pipeline in SPM12, which has been described previously  
 5 (Ashburner and Friston, 2000). Briefly, we created our study-specific DARTEL template based on  
 6 the template generated above. Then each  $T_1$ -weighted image was segmented into GM, WM and CSF  
 7 using the segmentation function in SPM12. Segmented images were then aligned to the DARTEL  
 8 template iteratively, spatially normalized, modulated and smoothed with an 8mm Gaussian kernel.  
 9 Volumes for the ROIs were calculated by summing all the white and grey matter voxels in the ROI  
 10 from the pre-processed images. To correct for the head size, the total intracranial volume (TIV) was  
 11 calculated as the sum of all voxels across the grey matter, white matter, and CSF segmented images.  
 12 Then ROI volume was corrected by simply dividing by TIV, a widely used method for volumetric  
 13 correction.

14

## 15 **2.8 Statistics**

16 Prior to performing statistical analyses, we first screened for outliers using the Grubbs' test by  
 17 applying a significant level of  $\alpha=0.01$  (Nation et al., 2019). All continuous variables were checked  
 18 for normality through examination of skewness and kurtosis. Log10-transformations were applied  
 19 where departures of normality were identified. Distribution normalization was confirmed before  
 20 parametric analyses. Unpaired Students' t-test was performed to compare the median  $AXR_{BBB}$  in  
 21 each ROI between NC group and MCI group. One-way analysis of variance (ANOVA) was  
 22 performed to explore the  $AXR_{BBB}$  change in each ROI among the three groups. One-way ANOVA  
 23 was also employed to assess the difference in age, education levels and the scores of neurological  
 24 tests, and the median ADC,  $\sigma$  and volume in all the ROIs among NC, MCI, and AD groups.  
 25 Categorical variables were analyzed by Pearson's  $\chi^2$  tests. Correlation analysis between  $AXR_{BBB}$   
 26 and cognitive functions were performed with linear regressions, with age, sex and education level  
 27 controlled.

28 All statistical analyses were performed in GraphPad Prism8.

29

### 3. Results

#### 3.1 Subjects' clinical characteristics

From March 2021 to January 2022, 52 participants were recruited for this sub-study from Beijing Tiantan Hospital and the local communities, including 27 healthy controls, 14 with MCI due to AD and 11 with AD. The baseline information of the subjects was showed in **Table 1**. There was no difference in age, gender and education level among groups. Statistical significance among groups was found in the neuropsychological tests, including MMSE, MoCA, CDR global scores, and RAVLT. The participants in NC group showed better performance than MCI and AD groups. Here, the MoCA scores seems to be lower than expected which could be presumably due to the linguistic and cultural differences between the original English version and the Chinese version of the scale or the lower education level of Chinese older adults (Yu et al., 2012).

**Table 1. Subject characteristics**


Variables	NC (n = 27)	MCI (n =14)	AD-Dementia (n = 11)	<i>P</i>
Average age, mean + SD	63.30±7.23	67.21±9.07	63.75±6.51	0.286
Gender female, n (%)	15, 55.5%	8, 57.1%	4, 36.4%	0.503
Years of education, mean ± SD	12.59±3.15	11.93±5.08	11.45±3.67	0.593
CDR global scores, mean ± SD	0	0.5	2.27±1.62	<0.001
MMSE, mean ± SD	26.07±1.88	19.86±6.3	10.09±6.43	<0.001
MoCA, mean ± SD	22.52±3.76	15.36±6.95	7.09±5.87	<0.001
RAVLT learn total, mean ± SD	37.33±9.13	25±9.33	8±10.06	<0.001
RAVLT long delayed recall, mean ± SD	6.37±3.00	2.36±3.13	0.18±0.6	<0.001

Abbreviations: CDR, Clinical Dementia Rating. MMSE, Mini Mental State Examination. MoCA, Montreal Cognitive Assessment. RAVLT, Rey Auditory Verbal Learning Test. *P* values were calculated either with One-way ANOVA or Pearson's  $\chi^2$  tests

#### 3.2. MCI shows increased BBB permeability in hippocampus

**Figure 3** showed VEXI results of hippocampus in MCI and NC groups. Comparing with that in NC group, the apparent diffusion coefficient *ADC*' of hippocampus in MCI showed larger values at each

mixing time  $t_m$  and recovered faster as  $t_m$  increased (**Figure 3A&3B**), in which the latter suggests faster water exchange across BBB (*i.e.*, increased BBB permeability, **Figure 3B**). Further quantitative modeling (**Eq. 1–3**) revealed that the  $AXR_{BBB}$  of hippocampus in MCI group ( $n = 14$ , group-averaged  $AXR_{BBB} = 1.63 \text{ s}^{-1}$ ) was significantly larger than those in NC group ( $n = 27$ ,  $AXR_{BBB} = 1.21 \text{ s}^{-1}$ ,  $p = 0.042$ , **Figure 3C**). Besides the hippocampus, no significant BBB changes between NC and MCI group were found in other cortical, subcortical or WM regions.




**Figure 3.** VEXI showed BBB breakdown of hippocampus in MCI group. (A) the averaged ADC' maps of all subjects in the MCI group and NC group at each mixing time. Here only the results in hippocampus were shown in color. (B) Representative  $ADC'(t_m)$  curves of the hippocampus in the NC (left) and MCI (right) group were shown. Here the first circle at  $t_m < 0 \text{ s}$  denoted as the equilibrium state ( $b_f = 0 \text{ s/mm}^2$ ). (C) Statistical comparison of  $AXR_{BBB}$  between NC and MCI in hippocampus. Unpaired Students'  $t$ -test. \*  $p < 0.05$ . NC, normal cognition group ( $n=27$ ); MCI, mild cognitive impairment group ( $n=14$ ).

### 3.3. The BBB breakdown gets worse and extends to more brain regions from MCI to AD

To investigate the BBB integrity as the disease progresses, we further analyzed the  $AXR_{BBB}$  change from NC to MCI, and then to AD. **Figure 4A-C** showed the averaged  $AXR_{BBB}$  maps of all subjects in NC, MCI, and AD groups. In hippocampus, we found increased  $AXR_{BBB}$  as the disease progressed from MCI to AD (**Figure 4A**), suggesting more damage of BBB with severe cognitive dysfunction. Further ANOVA analyses revealed significant  $AXR_{BBB}$  changes in the hippocampus (F

1 = 4.75,  $p = 0.013$ , **Figure 4D**), which increased by 56.2% from NC to AD ( $p = 0.016$ , Tukey's post  
2 hoc test). In addition, the BBB permeability showed spatial patterns inside the hippocampus: the  
3 subregions close to CA1 showed the earliest  $AXR_{BBB}$  changes from NC to MCI. Due to the low  
4 spatial resolution of the current VEXI method, we didn't pursue further quantitative analysis of  
5 hippocampal subregions. In addition to hippocampus, thalamus and OFC also showed significantly  
6 increasing  $AXR_{BBB}$  (by 59.4% and 130.0%, respectively) from NC to AD ( $p = 0.0006$  and  $p = 0.0001$ ,  
7 respectively, Tukey's post hoc test after ANOVA analysis) but didn't show detectable BBB  
8 permeability changes from NC to MCI even in the unpaired Students' t test (**Figure 4E&4F**).



9  
10 **Figure 4.** VEXI showed BBB breakdown along with disease progression. (A-C) Averaged  $AXR_{BBB}$  maps of all  
11 subjects in the NC, MCI and AD groups in hippocampus, thalamus and OFC in the template space. Statistical  
12 comparison of  $AXR_{BBB}$  values in hippocampus (D), thalamus (E), and OFC (F) among the NC (n=27), MCI (n=14)  
13 and AD (n=11) groups.  $p$ , significance by ANOVA followed by Tukey's post hoc tests. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  
14  $p < 0.001$ . NC, normal cognition group; MCI, mild cognitive impairment group; AD, Alzheimer's disease.

15  
16 To eliminate the potential impact of different sex composition between AD and NC (though not  
17 significant), we performed permutation test by randomly choosing 7 females out of 15 in the NC  
18 group to ensure the NC group has roughly the same sex ratio as the AD group. Among all the 6435

combinations, 100% of them in thalamus and OFC and 94.6% of them in hippocampus showed significantly smaller AXR<sub>BBB</sub> than the AD group ( $p < 0.05$ , unpaired Students' t-test), demonstrating the above results were not biased by the sex composition variance.


Hippocampal atrophy is a well-established biomarker in AD. In this study, we also found the significant reduction of hippocampus volume from NC to MCI and from MCI to AD. In fact, all the selected brain regions showed significant volume reduction in the AD group (**Figure S1**). To further demonstrate that our AXR<sub>BBB</sub> results in the template space were not affected by the brain morphology changes and these registration steps from subject's native space to template space, the same ROI-based VEXI parameter analysis were also performed in the subjects' native space (see methods). The hippocampus and other brain ROIs in each subject were manually drawn by one experienced neurologist and the CSF voxels were also carefully removed. Further ANOVA test on the three groups found significant differences in AXR<sub>BBB</sub> only on the same three brain regions (hippocampus, thalamus, and OFC) (Supplementary Information **Figure S2**). These results agree with the findings in the template space (Figure 4) and further demonstrates the reliability of our results in the template space.

### 3.4. Correlation between BBB breakdown and cognitive dysfunction

Linear regressions were used to assess potential correlations between BBB impairment and cognitive dysfunction in all subjects and subjects except AD group. As shown in **Figure 5** although the AXR<sub>BBB</sub> of all the three brain regions showed significant and negative correlations with the MoCA score in all subjects ( $r = -0.44$ ,  $p = 0.001$  in hippocampus,  $r = -0.50$ ,  $p = 0.0002$  in thalamus and  $r = -0.53$ ,  $p < 0.0001$  in OFC), only in hippocampus this correlation remained significant in the absence of AD group ( $r = -0.32$ ,  $p = 0.043$ ), suggesting that the worse cognitive function is associated with larger hippocampal BBB impairment while the BBB impairment is related to cognitive dysfunction in thalamus and OFC only at a late stage of the disease. Further statistics revealed that the AXR<sub>BBB</sub> of hippocampus, thalamus, and OFC in all subjects are all significantly associated with cognitive performance, such as MMSE, MoCA, RAVLT learn total and RAVLT long



delayed recall, independent of age, sex and education (Table 2). We also did the correlation analysis between AXR<sub>BBB</sub> of the three brain regions and other neurological tests in the absent of AD group. Similar as the above MoCA result, only in hippocampus the correlations remained significant or close to significant (except for RAVLT long delayed recall) (Table S1).



**Figure 5.** Larger AXR<sub>BBB</sub> was found to be associated with lower MoCA score in hippocampus(A), thalamus(B) and orbital frontal cortex(C). However, in the absence of AD data, the correlation between AXR<sub>BBB</sub> and MoCA only remained in hippocampus. Here each dot denoted the data from each subject (black for NC and MCI, blue for AD). The solid and dotted line denoted the linear regression results in all the data and in the absence of AD data, respectively, along with the correlation coefficients (and *p* values) labeled after solid and dotted lines.

**Table 2 Linear regression of BBB impairment and cognitive performance**


Variable	Hippocampus AXR <sub>BBB</sub>			OFC AXR <sub>BBB</sub>			Thalamus AXR <sub>BBB</sub>		
	B	95% CI	<i>p</i>	B	95% CI	<i>p</i>	B	95% CI	<i>p</i>
MMSE	-4.98	[-7.91, -2.05]	0.001	-2.71	[-3.92, -1.50]	<0.001	-6.56	[-10.07, -3.05]	<0.001
MoCA	-5.80	[-8.68, -2.92]	<0.001	-2.49	[-3.91, -1.38]	<0.001	-6.42	[-9.97, -2.88]	0.001
RAVLT total learning	-8.84	[-14.41, -3.28]	0.002	-4.16	[-6.56, -1.76]	0.001	-14.09	[-20.35, -7.83]	<0.001
RAVLT long DR	-1.62	[-3.06, -0.18]	0.028	-0.69	[-1.32, -0.07]	0.031	-2.02	[-3.79, -0.026]	0.025

MMSE, Minimum Mental State Examination. MoCA, Montreal Cognitive Assessment. RAVLT, Rey Auditory Verbal Learning Test. DR, delayed recall. B, unstandardized regression coefficient. CI, confidence interval.

### 3.5. Changes in other VEXI metrics along the progression of AD



Significant increase in  $ADC_0$  was found as the disease progress in hippocampus, thalamus, and OFC (Figure 6A-6C). ANOVA analyses revealed significant  $ADC_0$  changes in the hippocampus ( $F = 14.93$ ,  $p < 0.0001$ , Figure 6A), which increased by 44.2% from NC to AD ( $p < 0.0001$ , Tukey's post hoc test). OFC showed the similar patterns from NC to AD with  $ADC_0$  increased by 16.4% (ANOVA test,  $F = 7.37$ ,  $p = 0.0016$ , Figure 6C). In thalamus, significant  $ADC_0$  increase was found from NC to MCI by 6% though no increase was found from MCI to AD ( $F = 4.65$ ,  $p = 0.014$ , Figure 6B). All the other 5 brain ROIs, including caudate, striatum, IC, CC, and WSWM, also showed significant  $ADC_0$  increases from NC to AD (Figure S3). As for filter efficiency  $\sigma$ , significant decreases in  $\sigma$  from NC to AD were only found in thalamus (Figure 6E) and caudate nucleus (Figure S3). No significant changes in  $\sigma$  were found in other brain regions.



**Figure 6. Changes in the other VEXI metrics,  $ADC_0$  and  $\sigma$ , along the progression of AD.** Significant  $ADC_0$  increase was found in hippocampus (A), thalamus (B), and OFC (C) in the progression of AD. No significant  $\sigma$  changes were found in hippocampus (D) and OFC (F), meanwhile thalamus (E) shows a significant decrease from NC to AD.  $p$ , significance by ANOVA followed by Tukey's post hoc tests. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . NC, normal cognition group ( $n=27$ ); MCI, mild cognitive impairment group ( $n=14$ ); AD, Alzheimer's disease ( $n=11$ ).

1

## 2 **4. Discussion**

3 BBB breakdown is an essential pathophysiological process in AD and leads to the accumulation of  
4 potentially neurotoxic blood-derived products in the brain that normally do not go across BBB.  
5 Most neuroimaging studies that assessing BBB integrity in AD need the administration of a contrast  
6 agent to characterize the vascular leakage of the contrast agent. In this study, we first assessed the  
7 feasibility of vascular water exchange imaging (VEXI), a special diffusion MRI method assessing  
8 the speed of water exchange across BBB without the requirement of contrast agent, in detecting the  
9 BBB breakdown in AD. We found VEXI could detect the subtle BBB breakdown in the MCI group  
10 in comparison with NC, which specifically happened in the hippocampus. We then found BBB  
11 breakdown got worse from MCI to AD and extended to the thalamus and OFC regions. Furthermore,  
12 the BBB permeability to water detected by VEXI showed a significant correlation with the cognitive  
13 dysfunction. Taken together, our results have demonstrated the feasibility of VEXI in the detection  
14 of BBB breakdown in AD and VEXI as a potential contrast-free neuroimaging method in the long-  
15 term studies of a large population.

16

17 Hippocampus, a region critical for learning and memory, shows BBB breakdown in aging and early  
18 AD (Sweeney et al., 2018). It has been demonstrated that BBB breakdown is an early event in aging  
19 human brain that begins in the hippocampus using dynamic-contrast enhanced MRI (DCE-MRI)  
20 and this BBB breakdown is correlated with injury to BBB associated pericytes and may contribute  
21 to cognitive impairment (Montagne et al., 2015). In AD patients, BBB breakdown in hippocampus  
22 was detected by using DCE-MRI methods and shown as an early sign of cognitive dysfunction  
23 independent of A $\beta$  and/or tau changes (Nation et al., 2019) but related to APOE4 (Montagne et al.,  
24 2020). In this study, we have also found faster water exchange across BBB (i.e.,  $AXR_{BBB}$ ) in the  
25 hippocampus in AD, which demonstrates the BBB breakdown in the hippocampus and agrees with  
26 these literatures. More importantly, the BBB breakdown in the hippocampus detected in VEXI  
27 correlates with cognitive dysfunction and this correlation remains in the absence of AD data,  
28 suggesting its potential value as a biomarker of cognitive impairment even in the early AD phase.

29

1 In this study, we have also demonstrated the BBB breakdown of the OFC in AD, which is in line  
2 with the previous studies using DCE-MRI methods (van de Haar et al., 2017, 2016). The orbital  
3 frontal cortex is a region involved in awareness and metacognitive processes, in line with an  
4 abundant literature (McGlynn and Schacter, 1989). Studies with PET (Salmon et al., 2006) and  
5 SPECT (Mimura and Yano, 2006) have already reported a link between anosognosia in AD and  
6 OFC dysfunction. A previous research has shown a significant loss of pericytes in the frontal cortex  
7 in AD patients, which is correlated with BBB leakage (Sengillo et al., 2013).

8

9 In the comparison between AD and NC, the thalamus also showed significant BBB breakdown using  
10 VEXI, which is not reported in recent DCE-MRI studies (Montagne et al., 2020, 2015; Nation et al.,  
11 2019). This is not surprising as a previous study on AD rat model found that water exchange across  
12 BBB was a more sensitive biomarker than the vascular leakage of MRI contrast agent (e.g., transfer  
13 constant  $K^{\text{trans}}$ ) in the detection of subtle BBB breakdown (Dickie et al., 2019). Since water molecule  
14 is much smaller than contrast agent molecule, the biomarker of water exchange across BBB showed  
15 BBB breakdown in several brain regions (including hippocampus, thalamus, and cortex) in this AD  
16 rat model while  $K^{\text{trans}}$  failed to detect any BBB breakdown (Dickie et al., 2019). Indeed, some other  
17 studies using DCE-MRI have also reported the BBB leakage in deep gray matter and cortex (van de  
18 Haar et al., 2017). Thalamus, once viewed as passively receiving information from the basal ganglia  
19 limbic system and cerebellum, then relaying information to the cerebral cortex, is becoming  
20 increasingly acknowledged as actively regulating the information transmitted to cortical areas (B.  
21 et al., 2013). Evidence reveals that lesions to higher-order thalamic areas, such as the pulvinar and  
22 mediodorsal nucleus, can produce severe attention and memory deficits (Baxter, 2013; Bradfield et  
23 al., 2013), suggesting an important role for the thalamus in cognition. Recent studies have also  
24 shown the atrophy of thalamus in AD, which has also been proven in this study, and its potential  
25 role in the cognitive dysfunction (De Jong et al., 2008; Pardilla-Delgado et al., 2021).

26

27 For the other VEXI metrics,  $ADC_0$  shows significant increases along the progression of AD in all  
28 the selected brain regions, which agrees with the observed mean diffusivity (MD) or apparent  
29 diffusion coefficient (ADC) in MCI (or AD) in comparison with NC in previous studies (Altamura

et al., 2016; Kantarci et al., 2005; Scola et al., 2010; Takahashi et al., 2017) . Hippocampal ADC has been demonstrated as an effective predictor of the conversion from amnesic MCI to AD(Kantarci et al., 2005). Beyond hippocampus, a further study has also found the MD increase in the whole brain and some manually segmented ROIs along the trajectory from NC to MCI and to AD (Scola et al., 2010). The filter efficiency  $\sigma$  is a more complex parameter, which can be affected by the vascular water mole fraction and the ADCs of water in both intra- and extra-vascular space (see Eq. 5 in Bai et al., 2020). Both global and regional cerebra hypoperfusion has been demonstrated in AD and during the preclinical phase of AD (i.e., MCI) (Austin et al., 2011; Binnewijzend et al., 2016).Hypoperfusion could result to decreased ADC of intravascular water and/or decreased vascular water mole fraction (Le Bihan, 2019; Zhu et al., 2020). These factors, along with the increased ADC of extravascular water could explain the decreased  $\sigma$  in some brain regions from NC to AD, though most regions don't show significant changes. However, conflict results have also been reported. In a recent study using IVIM-DWI method, the detected vascular water mole fraction was found to increase with cognitive decline (Bergamino et al., 2020). The good news is that these two VEXI metrics are independent from  $AXR_{BBB}$  estimation (Eq. 4) and the changes in  $ADC_0$  or  $\sigma$  will not affect the accuracy of  $AXR_{BBB}$  estimation.

Several limitations and future works of this study should be clarified. At first, though previous study has demonstrated the increased BBB permeability to water is associated with the reduced expression of the tight junction protein occludin in AD rat model (Dickie et al., 2019) and CSF A $\beta$ 42 concentration levels in healthy older human adults (Gold et al., 2021), it is still highly desired to provide further pathophysiological explanations of the increased BBB permeability to water molecule in human AD. For instance, CSF levels of soluble platelet-derived growth factor receptor  $\beta$  (sPDGFR $\beta$ ) are one of the markers to assess the BBB-associated pericytes that play a key role in maintaining the BBB integrity (Sagare et al., 2015) and can be used to compare with the VEXI results in future. Another limitation is the small sample size, though careful statistics were performed. It is highly desired to test VEXI in a large sample and in longitudinal studies. Third,  $AXR_{BBB}$  could potentially be biased from intravascular water efflux rate constant  $k_{fs}$  by the difference in vessel density among different groups (Eq. 4), but this bias (<5%, Bai et al., 2020) is

negligible in comparison with the relatively large AXR<sub>BBB</sub> changes among different groups (>30%).  
Forth, the current VEXI still suffers from low spatial resolution, which limits further analysis on the  
subregions of hippocampus, thalamus, and other brain regions. Improving the spatial resolution of  
VEXI without scarifying the signal-to-noise quality is warranted in future studies. At last, it is  
interesting to study the age-dependence of the BBB permeability to water molecules using the same  
MRI method (e.g., VEXI) in future. Due to the acquisition parameter differences between this study  
and our previous work on young and healthy subjects (Bai et al., 2020), it is hard to compare the  
results in these two studies directly.

9

## 10 **Acknowledgments**

We would like to thank all the subjects for their participation in the study. We appreciate the  
help and work of all related clinicians, statisticians, imaging technicians and coordinators who  
participated in this study. This study is supported by grants from National Natural Science  
Foundation of China (NSFC) (Grant No. 81873894, Grant No. 82111530201), Beijing Municipal  
Science & Technology Commission (Grant No. Z181100001518005), Natural Science  
Foundation of Zhejiang Province, China (Grant No. LR20H180001), Strategic Priority Research  
Program of the Chinese Academy of Sciences (XDB39000000), and the MOE Frontier Science  
Center for Brain Science & Brain-Machine Integration, Zhejiang University.

19

20

# References

- 1 Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A.,  
2 Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps,  
3 C.H., 2011. The diagnosis of mild cognitive impairment due to Alzheimer's disease:  
4 Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on  
5 diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement.*  
6 <https://doi.org/10.1016/j.jalz.2011.03.008>
- 7 Altamura, C., Scrascia, F., Quattrocchi, C.C., Errante, Y., Gangemi, E., Curcio, G., Ursini, F.,  
8 Silvestrini, M., Maggio, P., Zobel, B.B., Rossini, P.M., Pasqualetti, P., Falsetti, L., Vernieri, F.,  
9 2016. Regional MRI diffusion, white-matter hyperintensities, and cognitive function in  
10 Alzheimer's disease and vascular dementia. *J. Clin. Neurol.*  
11 <https://doi.org/10.3988/jcn.2016.12.2.201>
- 12 Arvanitakis, Z., Capuano, A.W., Leurgans, S.E., Bennett, D.A., Schneider, J.A., 2016. Relation of  
13 cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people:  
14 a cross-sectional study. *Lancet Neurol.* [https://doi.org/10.1016/S1474-4422\(16\)30029-1](https://doi.org/10.1016/S1474-4422(16)30029-1)
- 15 Ashburner, J., Friston, K.J., 2000. Voxel-based morphometry - The methods. *Neuroimage.*  
16 <https://doi.org/10.1006/nimg.2000.0582>
- 17 Austin, B.P., Nair, V.A., Meier, T.B., Xu, G., Rowley, H.A., Carlsson, C.M., Johnson, S.C.,  
18 Prabhakaran, V., 2011. Effects of hypoperfusion in Alzheimer's disease. *Adv. Alzheimer's Dis.*  
19 <https://doi.org/10.3233/978-1-60750-793-2-253>
- 20 Avants, B.B., Tustison, N.J., Song, G., Cook, P.A., Klein, A., Gee, J.C., 2011. A reproducible  
21 evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage.*  
22 <https://doi.org/10.1016/j.neuroimage.2010.09.025>
- 23 Avants, B.B., Yushkevich, P., Pluta, J., Minkoff, D., Korczykowski, M., Detre, J., Gee, J.C., 2010. The  
24 optimal template effect in hippocampus studies of diseased populations. *Neuroimage.*  
25 <https://doi.org/10.1016/j.neuroimage.2009.09.062>
- 26 B., Z., Y., L., Z., Z., N., A., H., Y., P., W., L., W., X., Z., T., J., 2013. Impaired functional connectivity  
27 of the thalamus in Alzheimer's disease and mild cognitive impairment: A resting-state fMRI  
28 study. *Curr. Alzheimer Res.*
- 29 Bai, R., Li, Z., Sun, C., Hsu, Y., Liang, H., Bassar, P., 2020. Feasibility of filter-exchange imaging  
30 (FEXI) in measuring different exchange processes in human brain. *Neuroimage* 219, 117039.  
31 <https://doi.org/10.1016/j.neuroimage.2020.117039>
- 32 Baxter, M.G., 2013. Mediodorsal thalamus and cognition in nonhuman primates. *Front. Syst. Neurosci.*  
33 <https://doi.org/10.3389/fnsys.2013.00038>
- 34 Bergamino, M., Nespodzany, A., Baxter, L.C., Burke, A., Caselli, R.J., Sabbagh, M.N., Walsh, R.R.,  
35 Stokes, A.M., 2020. Preliminary Assessment of Intravoxel Incoherent Motion Diffusion-  
36 Weighted MRI (IVIM-DWI) Metrics in Alzheimer's Disease. *J. Magn. Reson. Imaging.*  
37 <https://doi.org/10.1002/jmri.27272>
- 38 Binnewijzend, M.A.A., Benedictus, M.R., Kuijter, J.P.A., van der Flier, W.M., Teunissen, C.E., Prins,  
39 N.D., Wattjes, M.P., van Berckel, B.N.M., Scheltens, P., Barkhof, F., 2016. Cerebral perfusion in  
40 the predementia stages of Alzheimer's disease. *Eur. Radiol.* [https://doi.org/10.1007/s00330-015-](https://doi.org/10.1007/s00330-015-3834-9)  
41 3834-9
- 42 Bradfield, L.A., Hart, G., Balleine, B.W., 2013. The role of the anterior, mediodorsal, and

- 1       parafascicular thalamus in instrumental conditioning. *Front. Syst. Neurosci.*
- 2       <https://doi.org/10.3389/fnsys.2013.00051>
- 3       De Jong, L.W., Van Der Hiele, K., Veer, I.M., Houwing, J.J., Westendorp, R.G.J., Bollen, E.L.E.M.,
- 4       De Bruin, P.W., Middelkoop, H.A.M., Van Buchem, M.A., Van Der Grond, J., 2008. Strongly
- 5       reduced volumes of putamen and thalamus in Alzheimer's disease: An MRI study. *Brain*.
- 6       <https://doi.org/10.1093/brain/awn278>
- 7       Dickie, B.R., Parker, G.J.M., Parkes, L.M., 2020. Measuring water exchange across the blood-brain
- 8       barrier using MRI. *Prog. Nucl. Magn. Reson. Spectrosc.*
- 9       <https://doi.org/10.1016/j.pnmrs.2019.09.002>
- 10      Dickie, B.R., Vandesquille, M., Ulloa, J., Boutin, H., Parkes, L.M., Parker, G.J.M., 2019. Water-
- 11      exchange MRI detects subtle blood-brain barrier breakdown in Alzheimer's disease rats.
- 12      *Neuroimage* 184, 349–358. <https://doi.org/10.1016/j.neuroimage.2018.09.030>
- 13      Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., Yang, Z., Chu, C., Xie, S., Laird, A.R., Fox,
- 14      P.T., Eickhoff, S.B., Yu, C., Jiang, T., 2016. The Human Brainnetome Atlas: A New Brain Atlas
- 15      Based on Connectional Architecture. *Cereb. Cortex*. <https://doi.org/10.1093/cercor/bhw157>
- 16      Gold, B.T., Shao, X., Sudduth, T.L., Jicha, G.A., Wilcock, D.M., Seago, E.R., Wang, D.J.J., 2021.
- 17      Water exchange rate across the blood-brain barrier is associated with CSF amyloid- $\beta$  42 in
- 18      healthy older adults. *Alzheimer's Dement.* <https://doi.org/10.1002/alz.12357>
- 19      He, X., Raichle, M.E., Yablonskiy, D.A., 2012. Transmembrane dynamics of water exchange in human
- 20      brain. *Magn. Reson. Med.* <https://doi.org/10.1002/mrm.23019>
- 21      He, X., Wengler, K., Schweitzer, M.E., 2018. Diffusion sensitivity of 3D-GRASE in arterial spin
- 22      labeling perfusion. *Magn. Reson. Med.* <https://doi.org/10.1002/mrm.27058>
- 23      Iadecola, C., 2017. The Neurovascular Unit Coming of Age: A Journey through Neurovascular
- 24      Coupling in Health and Disease. *Neuron*. <https://doi.org/10.1016/j.neuron.2017.07.030>
- 25      Iturria-Medina, Y., Sotero, R.C., Toussaint, P.J., Mateos-Pérez, J.M., Evans, A.C., Weiner, M.W.,
- 26      Aisen, P., Petersen, R., Jack, C.R., Jagust, W., Trojanowski, J.Q., Toga, A.W., Beckett, L., Green,
- 27      R.C., Saykin, A.J., Morris, J., Shaw, L.M., Khachaturian, Z., Sorensen, G., Kuller, L., Raichle,
- 28      M., Paul, S., Davies, P., Fillit, H., Hefti, F., Holtzman, D., Mesulam, M. Marcel, Potter, W.,
- 29      Snyder, P., Schwartz, A., Montine, T., Thomas, R.G., Donohue, M., Walter, S., Gessert, D.,
- 30      Sather, T., Jiminez, G., Harvey, D., Bernstein, M., Fox, N., Thompson, P., Schuff, N., Borowski,
- 31      B., Gunter, J., Senjem, M., Vemuri, P., Jones, D., Kantarci, K., Ward, C., Koeppe, R.A., Foster,
- 32      N., Reiman, E.M., Chen, K., Mathis, C., Landau, S., Cairns, N.J., Householder, E., Taylor-
- 33      Reinwald, L., Lee, V., Korecka, M., Figurski, M., Crawford, K., Neu, S., Foroud, T.M., Potkin,
- 34      S., Shen, L., Faber, K., Kim, S., Nho, K., Thal, L., Buckholtz, N., Albert, Marylyn, Frank, R.,
- 35      Hsiao, J., Kaye, J., Quinn, J., Lind, B., Carter, R., Dolen, S., Schneider, L.S., Pawluczyk, S.,
- 36      Beccera, M., Teodoro, L., Spann, B.M., Brewer, J., Vanderswag, H., Fleisher, A., Heidebrink,
- 37      J.L., Lord, J.L., Mason, S.S., Albers, C.S., Knopman, D., Johnson, Kris, Doody, R.S.,
- 38      Villanueva-Meyer, J., Chowdhury, M., Rountree, S., Dang, M., Stern, Y., Honig, L.S., Bell,
- 39      K.L., Ances, B., Carroll, M., Leon, S., Mintun, M.A., Schneider, S., Oliver, A., Marson, D.,
- 40      Griffith, R., Clark, D., Geldmacher, D., Brockington, J., Roberson, E., Grossman, H., Mitsis, E.,
- 41      De Toledo-Morrell, L., Shah, R.C., Duara, R., Varon, D., Greig, M.T., Roberts, P., Albert,
- 42      Marilyn, Onyike, C., D'Agostino, D., Kielb, S., Galvin, J.E., Cerbone, B., Michel, C.A., Rusinek,
- 43      H., De Leon, M.J., Glodzik, L., De Santi, S., Doraiswamy, P.M., Petrella, J.R., Wong, T.Z.,
- 44      Arnold, S.E., Karlawish, J.H., Wolk, D., Smith, C.D., Jicha, G., Hardy, P., Sinha, P., Oates, E.,



Conrad, G., Lopez, O.L., Oakley, M., Simpson, D.M., Porsteinsson, A.P., Goldstein, B.S.,  
Martin, K., Makino, K.M., Ismail, M.S., Brand, C., Mulnard, R.A., Thai, G., Mc-Adams-Ortiz,  
C., Womack, K., Mathews, D., Quiceno, M., Diaz-Arrastia, R., King, R., Weiner, M., Martin-  
Cook, K., DeVous, M., Levey, A.I., Lah, J.J., Cellar, J.S., Burns, J.M., Anderson, H.S.,  
Swerdlow, R.H., Apostolova, L., Tingus, K., Woo, E., Silverman, D.H.S., Lu, P.H., Bartzokis,  
G., Graff-Radford, N.R., Parfitt, F., Kendall, T., Johnson, H., Farlow, M.R., Hake, A., Matthews,  
B.R., Herring, S., Hunt, C., Van Dyck, C.H., Carson, R.E., MacAvoy, M.G., Chertkow, H.,  
Bergman, H., Hosein, C., Black, S., Stefanovic, B., Caldwell, C., Hsiung, G.Y.R., Feldman, H.,  
Mudge, B., Assaly, M., Kertesz, A., Rogers, J., Bernick, C., Munic, D., Kerwin, D., Mesulam,  
Marek Marsel, Lipowski, K., Wu, C.K., Johnson, N., Sadowsky, C., Martinez, W., Villena, T.,  
Turner, R.S., Johnson, Kathleen, Reynolds, B., Sperling, R.A., Johnson, K.A., Marshall, G.,  
Frey, M., Lane, B., Rosen, A., Tinklenberg, J., Sabbagh, M.N., Belden, C.M., Jacobson, S.A.,  
Sirrel, S.A., Kowall, N., Killiany, R., Budson, A.E., Norbash, A., Johnson, P.L., Allard, J.,  
Lerner, A., Ogrocki, P., Hudson, L., Fletcher, E., Carmichael, O., Olichney, J., DeCarli, C.,  
Kittur, S., Borrie, M., Lee, T.Y., Bartha, R., Johnson, S., Asthana, S., Carlsson, C.M., Potkin,  
S.G., Preda, A., Nguyen, D., Tariot, P., Reeder, S., Bates, V., Capote, H., Rainka, M., Scharre,  
D.W., Kataki, M., Adeli, A., Zimmerman, E.A., Celmins, D., Brown, A.D., Pearlson, G.D.,  
Blank, K., Anderson, K., Santulli, R.B., Kitzmiller, T.J., Schwartz, E.S., Sink, K.M., Williamson,  
J.D., Garg, P., Watkins, F., Ott, B.R., Querfurth, H., Tremont, G., Salloway, S., Malloy, P.,  
Correia, S., Rosen, H.J., Miller, B.L., Mintzer, J., Spicer, K., Bachman, D., Finger, E., Pasternak,  
S., Rachinsky, I., Drost, D., Pomara, N., Hernando, R., Sarrael, A., Schultz, S.K., Ponto, L.L.B.,  
Shim, H., Smith, K.E., Relkin, N., Chaing, G., Raudin, L., Smith, A., Fargher, K., Raj, B.A.,  
Neylan, T., Grafman, J., Davis, M., Morrison, R., Hayes, J., Finley, S., Friedl, K., Fleischman,  
D., Arfanakis, K., James, O., Massoglia, D., Fruehling, J.J., Harding, S., Peskind, E.R., Petrie,  
E.C., Li, G., Yesavage, J.A., Taylor, J.L., Furst, A.J., 2016. Early role of vascular dysregulation  
on late-onset Alzheimer's disease based on multifactorial data-driven analysis. *Nat. Commun.*  
<https://doi.org/10.1038/ncomms11934>

Kantarci, K., Petersen, R.C., Boeve, B.F., Knopman, D.S., Weigand, S.D., O'Brien, P.C., Shiung,  
M.M., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Jack, C.R., 2005. DWI predicts future  
progression to Alzheimer disease in amnesic mild cognitive impairment. *Neurology.*  
<https://doi.org/10.1212/01.WNL.0000153076.46126.E9>

Kisler, K., Nelson, A.R., Montagne, A., Zlokovic, B. V., 2017. Cerebral blood flow regulation and  
neurovascular dysfunction in Alzheimer disease. *Nat. Rev. Neurosci.*  
<https://doi.org/10.1038/nrn.2017.48>

Lasič, S., Nilsson, M., Lätt, J., Ståhlberg, F., Topgaard, D., 2011. Apparent exchange rate mapping  
with diffusion MRI. *Magn. Reson. Med.* 66, 356–365. <https://doi.org/10.1002/mrm.22782>

Le Bihan, D., 2019. What can we see with IVIM MRI? *Neuroimage.*  
<https://doi.org/10.1016/j.neuroimage.2017.12.062>

Lin, Z., Li, Y., Su, P., Mao, D., Wei, Z., Pillai, J.J., Moghekar, A., van Osch, M., Ge, Y., Lu, H., 2018.  
Non-contrast MR imaging of blood-brain barrier permeability to water. *Magn. Reson. Med.*  
<https://doi.org/10.1002/mrm.27141>

Mazziotta, J., Toga, A., Evans, A., Fox, P., Lancaster, J., Zilles, K., Woods, R., Paus, T., Simpson, G.,  
Pike, B., Holmes, C., Collins, L., Thompson, P., MacDonald, D., Iacoboni, M., Schormann, T.,  
Amunts, K., Palomero-Gallagher, N., Geyer, S., Parsons, L., Narr, K., Kabani, N., Le Goualher,



- 1 G., Boomsma, D., Cannon, T., Kawashima, R., Mazoyer, B., 2001. A probabilistic atlas and  
2 reference system for the human brain: International Consortium for Brain Mapping (ICBM).  
3 Philos. Trans. R. Soc. B Biol. Sci. <https://doi.org/10.1098/rstb.2001.0915>
- 4 Mazziotta, J.C., Toga, A.W., Evans, A., Fox, P., Lancaster, J., 1995. A probabilistic atlas of the human  
5 brain: theory and rationale for its development. The International Consortium for Brain Mapping  
6 (ICBM). Neuroimage.
- 7 McGlynn, S.M., Schacter, D.L., 1989. Unawareness of deficits in neuropsychological syndromes. J.  
8 Clin. Exp. Neuropsychol. Off. J. Int. Neuropsychol. Soc.  
9 <https://doi.org/10.1080/01688638908400882>
- 10 McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., Klunk, W.E.,  
11 Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P.,  
12 Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., 2011. The diagnosis of dementia due to  
13 Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's  
14 Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement.  
15 <https://doi.org/10.1016/j.jalz.2011.03.005>
- 16 Mimura, M., Yano, M., 2006. Memory Impairment and Awareness of Memory Deficits in Early-Stage  
17 Alzheimer's Disease. Rev. Neurosci. <https://doi.org/10.1515/revneuro.2006.17.1-2.253>
- 18 Minoshima, S., Giordani, B., Berent, S., Frey, K.A., Foster, N.L., Kuhl, D.E., 1997. Metabolic  
19 reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol.  
20 <https://doi.org/10.1002/ana.410420114>
- 21 Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., Toga, A.W.,  
22 Jacobs, R.E., Liu, C.Y., Amezcua, L., Harrington, M.G., Chui, H.C., Law, M., Zlokovic, B. V.,  
23 2015. Blood-Brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302.  
24 <https://doi.org/10.1016/j.neuron.2014.12.032>
- 25 Montagne, A., Nation, D.A., Sagare, A.P., Barisano, G., Sweeney, M.D., Chakhoyan, A., Pachicano, M.,  
26 Joe, E., Nelson, A.R., D'Orazio, L.M., Buennagel, D.P., Harrington, M.G., Benzinger, T.L.S., Fagan, A.M.,  
27 Ringman, J.M., Schneider, L.S., Morris, J.C., Reiman, E.M., Caselli, R.J., Chui, H.C., Tcw, J., Chen, Y., Pa, J.,  
28 Conti, P.S., Law, M., Toga, A.W., Zlokovic, B. V., 2020. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature 581, 71–76.  
29 <https://doi.org/10.1038/s41586-020-2247-3>
- 30 Mori, S., Wakana, S., Van Zijl, P.C.M., Nagae-Poetscher, L.M., 2005. MRI atlas of human white  
31 matter. Elsevier.
- 32 Nation, D.A., Sweeney, M.D., Montagne, A., Sagare, A.P., D'Orazio, L.M., Pachicano, M.,  
33 Sepehrband, F., Nelson, A.R., Buennagel, D.P., Harrington, M.G., Benzinger, T.L.S., Fagan, A.M.,  
34 Ringman, J.M., Schneider, L.S., Morris, J.C., Chui, H.C., Law, M., Toga, A.W., Zlokovic, B. V., 2019. Blood–brain barrier breakdown is an early biomarker of human cognitive  
35 dysfunction. Nat. Med. 25, 270–276. <https://doi.org/10.1038/s41591-018-0297-y>
- 36 Nilsson, M., Lätt, J., Van Westen, D., Brockstedt, S., Lasič, S., Ståhlberg, F., Topgaard, D., 2013. Noninvasive mapping of water diffusional exchange in the human brain using filter-exchange  
37 imaging. Magn. Reson. Med. 69, 1573–1581. <https://doi.org/10.1002/mrm.24395>
- 38 Ohene, Y., Harrison, I.F., Nahavandi, P., Ismail, O., Bird, E. V., Ottersen, O.P., Nagelhus, E.A.,  
39 Thomas, D.L., Lythgoe, M.F., Wells, J.A., 2019. Non-invasive MRI of brain clearance pathways  
40 using multiple echo time arterial spin labelling: an aquaporin-4 study. Neuroimage.  
41 <https://doi.org/10.1016/j.neuroimage.2018.12.026>

Pardilla-Delgado, E., Torrico-Teave, H., Sanchez, J.S., Ramirez-Gomez, L.A., Baena, A., Bocanegra, Y., Vila-Castelar, C., Fox-Fuller, J.T., Guzmán-Vélez, E., Martínez, J., Alvarez, S., Ochoa-Escudero, M., Lopera, F., Quiroz, Y.T., 2021. Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease. *Brain Commun.* <https://doi.org/10.1093/braincomms/fcab101>

Pierpaoli, C., Walker, L., Irfanoglu, M.O., Barnett, A., Basser, P., Chang, L.C., Koay, C., Pajevic, S., Rohde, G., Sarlls, J., 2010. TORTOISE: an integrated software package for processing of diffusion MRI data, in: ISMRM 18th Annual Meeting. Stockholm.

Sagare, A.P., Sweeney, M.D., Makshanoff, J., Zlokovic, B. V., 2015. Shedding of soluble platelet-derived growth factor receptor- $\beta$  from human brain pericytes. *Neurosci. Lett.* <https://doi.org/10.1016/j.neulet.2015.09.025>

Salmon, E., Perani, D., Herholz, K., Marique, P., Kalbe, E., Holthoff, V., Delbeuck, X., Beuthien-Baumann, B., Pelati, O., Lespagnard, S., Collette, F., Garraux, G., 2006. Neural correlates of anosognosia for cognitive impairment in Alzheimer's disease. *Hum. Brain Mapp.* <https://doi.org/10.1002/hbm.20203>

Scola, E., Bozzali, M., Agosta, F., Magnani, G., Franceschi, M., Sormani, M.P., Cercignani, M., Pagani, E., Falautano, M., Filippi, M., Falini, A., 2010. A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. *J. Neurol. Neurosurg. Psychiatry* 81, 798–805. <https://doi.org/10.1136/jnnp.2009.189639>

Sengillo, J.D., Winkler, E.A., Walker, C.T., Sullivan, J.S., Johnson, M., Zlokovic, B. V., 2013. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in alzheimer's disease. *Brain Pathol.* <https://doi.org/10.1111/bpa.12004>

Sweeney, M.D., Sagare, A.P., Zlokovic, B. V., 2018. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat. Rev. Neurol.* <https://doi.org/10.1038/nrneurol.2017.188>

Takahashi, H., Ishii, K., Kashiwagi, N., Watanabe, Y., Tanaka, H., Murakami, T., Tomiyama, N., 2017. Clinical application of apparent diffusion coefficient mapping in voxel-based morphometry in the diagnosis of Alzheimer's disease. *Clin. Radiol.* <https://doi.org/10.1016/j.crad.2016.11.002>

Toledo, J.B., Arnold, S.E., Raible, K., Bretschneider, J., Xie, S.X., Grossman, M., Monsell, S.E., Kukull, W.A., Trojanowski, J.Q., 2013. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain.* <https://doi.org/10.1093/brain/awt188>

van de Haar, H.J., Burgmans, S., Jansen, J.F.A., van Osch, M.J.P., van Buchem, M.A., Muller, M., Hofman, P.A.M., Verhey, F.R.J., Backes, W.H., 2017. Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease. *Radiology.* <https://doi.org/10.1148/radiol.2017164043>

van de Haar, H.J., Jansen, J.F.A., van Osch, M.J.P., van Buchem, M.A., Muller, M., Wong, S.M., Hofman, P.A.M., Burgmans, S., Verhey, F.R.J., Backes, W.H., 2016. Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging. *Neurobiol. Aging* 45, 190–196. <https://doi.org/10.1016/j.neurobiolaging.2016.06.006>

Wang, H., Golob, E.J., Su, M.Y., 2006. Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. *J. Magn. Reson. Imaging* 24, 695–700. <https://doi.org/10.1002/jmri.20669>

Wang, J., Fernández-Seara, M.A., Wang, S., St Lawrence, K.S., 2007. When perfusion meets diffusion:

1 In vivo measurement of water permeability in human brain. *J. Cereb. Blood Flow Metab.*  
2 <https://doi.org/10.1038/sj.jcbfm.9600398>  
3 Yu, J., Li, J., Huang, X., 2012. The Beijing version of the montreal cognitive assessment as a brief  
4 screening tool for mild cognitive impairment: A community-based study. *BMC Psychiatry.*  
5 <https://doi.org/10.1186/1471-244X-12-156>  
6 Zhang, C.E., Wong, S.M., Uiterwijk, R., Backes, W.H., Jansen, J.F.A., Jeukens, C.R.L.P.N., van  
7 Oostenbrugge, R.J., Staals, J., 2019. Blood–brain barrier leakage in relation to white matter  
8 hyperintensity volume and cognition in small vessel disease and normal aging. *Brain Imaging*  
9 *Behav.* 13, 389–395. <https://doi.org/10.1007/s11682-018-9855-7>  
10 Zhu, G., Federau, C., Wintermark, M., Chen, H., Marcellus, D.G., Martin, B.W., Heit, J.J., 2020.  
11 Comparison of MRI IVIM and MR perfusion imaging in acute ischemic stroke due to large  
12 vessel occlusion. *Int. J. Stroke.* <https://doi.org/10.1177/1747493019873515>  
13 Zlokovic, B. V., 2008. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders.  
14 *Neuron.* <https://doi.org/10.1016/j.neuron.2008.01.003>  
15